Madrigal Pharma (MDGL) option implied volatility into FDA approval
March 14, 2024 3:51 PM
Madrigal Pharma (NASDAQ: MDGL) 30-day option implied volatility is at 151; compared to its 52-week range of 49 to 176 into FDA approves Madrigal Pharmaceuticals' Rezdiffra.
